Literature DB >> 23449226

The changing epidemiology of liver disease in HIV patients.

Vincent Soriano1, Pablo Barreiro, Kenneth E Sherman.   

Abstract

Liver disease continues to be one of the leading causes of hospitalization and death in HIV-infected individuals. Important etiologies include both alcoholic and non-alcoholic steatohepatitis, and coinfection with hepatitis viruses B and C. While non-alcoholic fatty liver disease is increasingly diagnosed in this population, most cases of chronic hepatitis B can be well controlled with tenofovir-based regimens, and hepatitis C has entered a revolutionary era in which most patients may be cured with direct-acting antivirals. However, important gaps remain unaddressed. Hepatitis delta is a neglected disease, despite 15 million people being infected worldwide, and represents the most severe form of viral hepatitis. Hepatitis E is largely unrecognized, despite being the major cause of acute viral hepatitis worldwide and occasionally leading to chronicity in immunosuppressed individuals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449226

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  23 in total

1.  Causes of liver disease and its outcome in HIV-infected individuals.

Authors:  Suryanarayana Bettadpura Shamanna; Ramavath Raghu Ramulu Naik; Abdoul Hamide
Journal:  Indian J Gastroenterol       Date:  2016-07-20

Review 2.  The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Authors:  Ying Mu; Sunitha Kodidela; Yujie Wang; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2018-09-20       Impact factor: 3.889

3.  Human immunodeficiency virus and liver disease forum 2012.

Authors:  Kenneth E Sherman; David Thomas; Raymond T Chung
Journal:  Hepatology       Date:  2013-11-22       Impact factor: 17.425

4.  Analysis of HIV quasispecies suggests compartmentalization in the liver.

Authors:  Patricia K Penton; Jason T Blackard
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

5.  The burden, pattern and factors that contribute to periportal fibrosis in HIV-infected patients in an S. mansoni endemic rural Uganda.

Authors:  Ponsiano Ocama; Kenneth Christopher Opio; Emmanuel Seremba; Paul Ajal; Betty Stephanie Apica; Emmanuel Odongo Aginya
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

6.  Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.

Authors:  Minhee Kang; Kimberly Hollabaugh; Vinh Pham; Susan L Koletar; Kunling Wu; Marlene Smurzynski; Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

Review 7.  Update on HIV/HCV coinfection.

Authors:  Vincent Soriano; Eugenia Vispo; Jose Vicente Fernandez-Montero; Pablo Labarga; Pablo Barreiro
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.495

Review 8.  Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?

Authors:  Athanasios-Dimitrios Bakasis; Theodoros Androutsakos
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

9.  Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and Non-injection drug users from coastal Kenya.

Authors:  Mark K Webale; Mark W Kilongosi; Valentine Budambula; Raphael Lihana; Francis O Musumba; Anthony K Nyamache; Nancy L M Budambula; Aabid A Ahmed; Collins Ouma; Tom Were
Journal:  BMC Infect Dis       Date:  2015-07-30       Impact factor: 3.090

10.  Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users.

Authors:  Eric M Ndombi; Valentine Budambula; Mark K Webale; Francis O Musumba; Jesca O Wesongah; Erick Mibei; Aabid A Ahmed; Raphael Lihana; Tom Were
Journal:  Endocr Connect       Date:  2015-08-25       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.